A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison
Authors
Jones, R. J.Hussain, S. A.
Birtle, A. J.
Song, Yee Pei
Enting, D.
Faust, G.
Hilman, S.
Jagdev, S.
McGovern, U. B.
Parikh, O.
Lewis, A.
Soulis, E.
Trevethan, A.
Crabb, S. J.
Powles, T.
Affiliation
University of Glasgow, GlasgowIssue Date
2022
Metadata
Show full item recordCitation
Jones RJ, Hussain SA, Birtle AJ, Song YP, Enting D, Faust G, et al. A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison. Journal of Clinical Oncology. 2022 Jun;40(17). PubMed PMID: WOS:000891791500024.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.17_suppl.LBA4505Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.17_suppl.LBA4505Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.17_suppl.LBA4505